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One additional skin lightening or whitening quasi-drug (QD) has been developed and officially 
approved by the Ministry of Health, Labor and Welfare of Japan. The active ingredient niacinamide 
should be included in this review [1]. Its mechanism of skin lightening is based on the inhibition of 
melanosome transfer from melanocytes to keratinocytes. Niacinamide is listed in Table 1, which 
classifies compounds according to the mechanism of skin lightening QDs registered in Japan. 
2.15. Niacinamide (Obtained by Procter & Gamble Company in 2007) 
Niacinamide (also termed nicotinamide), a derivative of vitamin B3, has been shown to act as an 
anti-inflammatory agent in acne [2]. Niacinamide had no effect on the tyrosinase activity and melanin 
synthesis of cultured normal human melanocytes, however, it was found that niacinamide significantly 
decreased hyperpigmentation, such as melasma and solar lentigines, via inhibition of melanosome 
transfer from melanocytes to keratinocytes [3,4]. 
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Table 1. Mechanistic classification of skin lightening QDs approved by the MHLW of Japan. 
Target  Mechanism  Detail  Skin Lightening QD 
Melanocyte 
Inhibition of 
tyrosinase activity 
Anti-oxidation Ascorbic  acid/derivatives 
Chelating copper 
atoms 
Kojic acid     Ellagic acid 
Competitive 
inhibition 
Arbutin          Rucinol®   
4MSK            4-HPB 
 
Decrease of 
tyrosinase 
protein level 
Acceleration of Tyr 
degradation 
Linoleic acid 
Inhibition of Tyr 
maturation 
Magnolignan® 
Keratinocyte 
Inhibition of  
KC-MC signaling 
Inhibition of UV 
inflammation 
Chamomilla extract 
Tranexamic acid/derivative 
Melanocyte and 
Keratinocyte 
Inhibition of 
melanosome transfer 
Inhibition of melanin 
dispersion 
Niacinamide 
Epidermis 
Acceleration of 
epidermal turnover 
Desquamation 
of melanin 
Placental extract 
Adenosine mono-phosphate 
KC: keratinocyte; MC: melanocyte; Tyr: tyrosinase; UV: ultraviolet light. 
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